The "three medicines and three prescriptions" in the war epidemic play a big role
Chinese medicine is a major feature and highlight of the prevention and control of the new coronary pneumonia epidemic. In the absence of specific drugs and vaccines, China has taken advantage of the unique advantages of traditional Chinese medicine in treating disease, syndrome differentiation, and multi-target interventions, and has explored the formation of a system program featuring traditional Chinese medicine and integrated Chinese and Western medicine to treat patients. A vivid practice of medical inheritance and innovation. So, what has traditional Chinese medicine gained in this epidemic prevention and control? What are the implications for the future prevention and treatment of infectious diseases and public health emergency management in China?
In the fight against the new coronary pneumonia epidemic, Chinese medicine has played an important role, especially the clinically screened "three drugs and three prescriptions" have definite effects. Zhang Boli, academician of the Chinese Academy of Engineering and president of Tianjin University of Traditional Chinese Medicine, said that good medicine will appear after every major epidemic, so there is a sentence called "great epidemic produces good medicine"; Li Yu, director of the Science and Technology Department of the State Administration of Traditional Chinese Medicine also said, " "A good cure for epidemic disease" is a summary of the practical experience of the Chinese nation in fighting the disease for thousands of years.
Detailed explanation of "three medicines and three prescriptions"
Li Yu said that the State Council should set up a special class for traditional Chinese medicine under the scientific research team of the New Coronary Pneumonia Joint Prevention and Control Mechanism to coordinate the promotion of key scientific research work in the prevention and treatment of epidemics of traditional Chinese medicine and the establishment of a mid- and long-term infectious disease prevention and control mechanism. The Chinese medicine special class is led by the president of the Chinese Academy of Engineering Li Xiaohong, and the State Administration of Traditional Chinese Medicine fully cooperates with the Ministry of Science and Technology, the Ministry of Education, the National Development and Reform Commission, the National Health and Health Commission, the Ministry of Industry and Information Technology, the Chinese Academy of Sciences, the National Drug Administration Bureau and other departments jointly formed. An expert group is set up under the special class of traditional Chinese medicine, which is composed of academicians of the two academies, masters of traditional Chinese medicine, experts of traditional Chinese medicine, and pharmacy. The special class also has four task groups for clinical treatment, mechanism research, prescription screening and system construction. Related tasks. Among them, the clinical treatment group summarized and launched the effective prescription of "Three Medicines and Three Formulas" of traditional Chinese medicine represented by Qingfei Paidu Decoction based on the previous clinical observation, which played an important role in clinical treatment.
So, which three medicines does "three medicines and three prescriptions" mean? Which three parties?
According to reports, the "three medicines" are Jinhua Qinggan Granules, Lianhua Qingwen Granules and capsules, and Xuebijing Injection. Li Yu pointed out that these three drugs are all old drugs that have been approved in the market and have played an important role in the treatment of new coronary pneumonia this time, showing good clinical efficacy.
Jinhua Qinggan Granules is an effective Chinese medicine developed in 2009 against H1N1 influenza. The drug has a definite effect on the treatment of light and ordinary patients with new coronary pneumonia, can shorten the time of fever, not only can improve the recovery rate of lymphocytes and leukocytes, but also can improve related immunological indicators. Recently, Jinhua Qinggan Granule has been managed by the State Food and Drug Administration as a non-prescription drug of Class A, which can well meet the needs of clinical treatment. It is understood that Jinhua Qinggan Granules was a Chinese medicine specially developed for the influenza epidemic when the domestic influenza A-type H1N1 influenza pandemic occurred in 2009 when the domestic Western medicine Tamiflu reserve was seriously insufficient. Basic research was conducted by academicians of the Chinese Academy of Engineering and the Chinese Academy of Chinese Medical Sciences Chang Huang Luqi took the lead and participated in many units including the Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Institute of Laboratory Animals, Chinese Academy of Medical Sciences, School of Life Science and Bioengineering, Beijing Polytechnic University, etc., using internationally recognized and universal evaluation indicators and influenza virus strains. The in-vivo experiment combined with methods to study, confirmed that Jinhua Qinggan granules have antiviral, antipyretic, anti-inflammatory, immunomodulatory effects. Academician Wang Chen of the Chinese Academy of Engineering also led the establishment of a research group with 11 hospitals including Beijing Chaoyang Hospital and Beijing Respiratory Disease Research Institute to conduct a comparative study of the clinical effects of Tamiflu and Jinhua Qinggan in the treatment of H1N1 influenza. The study used internationally-based modern evidence-based medicine research methods. The conclusions of the study showed that the therapeutic effect of Jinhua Qinggan Granules is comparable to that of Tamiflu, and there are no side effects. The content of this research was published in the international authoritative medical journal "Internal Medicine Yearbook" in August 2011. This is also the first Chinese patent medicine in the history of Chinese medicine that has passed phase III clinical and evidence-based medicine.
Lianhua Qingwen Capsule shows good curative effect in treating light and ordinary patients, and it has obvious curative effect in relieving fever, cough, fatigue and other symptoms, and can effectively reduce the rate of turning weight. It is understood that Lianhua Qingwen is an innovative Chinese medicine developed in 2003 to treat influenza. Facing the SARS epidemic, Wu Yiling, an academician of the Chinese Academy of Engineering, formed a Chinese medicine research team against SARS virus, tapped the essence of Chinese medicine for the treatment of "epidemic" disease for two thousand years, formulated prescriptions, discussed techniques, and formulated standards. They are based on the three dynasties of Zhang Zhongjing's "Ma Xing Shi Gan Tang" in the Han Dynasty, "Rhubarb" which can be used to cure epidemic diseases in the Ming Dynasty, and "Yin Qiao San" by Wu Jutong in the Qing Dynasty, combined with modern Chinese medicine antiviral and anti-inflammatory The research results of the drug, and the addition of the "red rhododendron" that enhances the body's immunity, aromatizes the wet patchouli, gathers the wisdom of two thousand years of traditional Chinese medicine to treat exogenous fever, and develops the innovative Chinese medicine Lianhua Qingwen. As a representative of modern Chinese medicine, Lianhua Qingwen Capsule has gradually won the unanimous approval at home and abroad for its suppression and relief effect on the new coronary pneumonia epidemic.
Xuebijing injection can promote the elimination of inflammatory factors, and is mainly used for the early and mid-term treatment of severe and critically ill patients. It can improve the cure rate and discharge rate, and reduce the conversion probability of severe to critically ill. This medicine is a proprietary Chinese medicine developed and marketed during SARS in 2003. Xuebijing was founded by Wang Jinda, the founder and pioneer of critically ill emergency medicine in China, through continuous optimization of the Qing Dynasty "Xuefu Zhuyu Decoction" formula, which has been successfully developed over 30 years and consists of safflower, red peony, Chuanxiong, salvia and angelica , It has the functions of promoting blood circulation, removing blood stasis, cooling blood, nourishing blood, and disinfecting the poison. It is used for the treatment of infection-induced systemic inflammatory response syndrome and multiple organ dysfunction syndrome as indications. The name blood must be clean, which means that the endotoxins and inflammatory factors in the blood must be eliminated, and the blood must be kept clean. In 2003, the blood in the hospital preparations must be clean. It showed a clear effect in the treatment of SARS patients. Therefore, it entered the green channel for rapid approval of new anti-SARS drugs, and was approved for marketing in early 2004. It was exclusively produced by Hongri Pharmaceuticals and became a prevention and treatment. A major scientific and technological achievement of serious infectious diseases has filled the gap in the treatment of sepsis and multiple organ dysfunction syndrome.
"Sanfang" refers to the three prescriptions of Qingfei Paidu Decoction, Huashi Baidu Decoction, and Xuanfei Baidu Decoction. Qingfei Paidu Decoction is a fusion of five classic prescriptions derived from "Treatise on Febrile Diseases". On February 6, the National Health and Health Commission and the State Administration of Traditional Chinese Medicine obtained the clinical good results in the early stage. It is recommended to use Qingfei Paidu Decoction for the treatment of patients with various types of new coronary pneumonia, and after long-term clinical observation, Qingfei Paidu Decoction has shown an important role in blocking the development of light and common types to heavy and critical. At the same time, it also played a very good role in the rescue process of heavy and critical. Qingfei Paidu Decoction is a general prescription recommended in the national diagnosis and treatment plan. Huashi Baidu Fang and Xuanfei Baidu Fang are effective prescriptions summarized by the clinical observation of Huang Luqi's team and Zhang Boli's team in the first-line clinical treatment of Wuhan, which can block the development of the disease, improve symptoms, especially shorten It has a good effect on the course of disease.
Promote the transformation of results
Yang Sheng, deputy director of the Drug Registration Department of the State Food and Drug Administration, pointed out that the State Food and Drug Administration actively supports the characteristics of traditional Chinese medicine and supports the use of traditional Chinese medicine and traditional Chinese medicine preparations in medical institutions under the guidance of traditional Chinese medicine theory for the treatment of new coronary pneumonia.
Yang Sheng said that regarding the emergency approval work, the State Food and Drug Administration carried out the work in a scientific and orderly manner. One is to start the emergency approval work mechanism as soon as possible. It not only adheres to laws and regulations, but also handles special tasks to ensure that emergency approval is scientific, precise, orderly and efficient. The second is to actively engage in the research of drug research, and to receive and approve emergency approval applications and consultations for potential effective drugs. When the judgment is followed, the feedback to the research institution is quickly returned to jointly promote the progress of the project. The third is to carry out emergency review and approval in a race against time.
Yang Sheng said, taking the “three medicines and three prescriptions” of traditional Chinese medicine as an example, we formed a special expert group mainly composed of academicians of traditional Chinese medicine, especially the frontline experts of anti-epidemic clinics, to play a guiding role and organize special personnel and “three medicines and three prescriptions” Production enterprises and R & D units are actively connected to provide technical guidance and registration services. On the basis of the good results achieved in the early clinical practice of anti-epidemic, the transformation of the achievements of the "three drugs" has been accelerated, and the transformation of the achievements of the "three parties" is being stepped up. In addition, the State Food and Drug Administration also actively guides local governments to promulgate emergency policies for the preparation of emergency management of medical institutions, to carry out the filing, approval and adjustment of preparations of traditional Chinese medicine national medical institutions in accordance with laws and regulations, and to give full play to the role of traditional Chinese medicine in epidemic prevention and control . In the follow-up, the State Food and Drug Administration will continue to do its best in emergency approval work in accordance with the principles of "unified command, early intervention, follow-up evaluation, and scientific review" to ensure the need for the use of drugs for epidemic prevention and control.
It is reported that the State Food and Drug Administration has approved the treatment of new coronary pneumonia into the new drug indications of the "Three Drugs"; the Qingfei Paidu Granules and Huashibaidu Granules in the "Three Parties" have also been approved by the State Food and Drug Administration, Obtained the national clinical trial approval.
(Reporter Tian Yating)